TMS, Neurology and Migraine
Basic findings
It is generally accepted that migraine patients present an abnormal cortical activation pattern. TMS has the advantage of being able to assess cortical excitability in an atraumatic and repeatable manner and rTMS can modulate it. TMS has been used to search for cortical dysfunction in migraine (Oxford Handbook) and is being developed as both an acute and preventive treatment (Lipton & Pearlman 2010).
Ongoing research
Monitoring The Disease
The first study of motor cortex TMS in migraine was published in 1992 (Maertens de Noordhout) in a pilot study conducted between attacks in unilateral migraine with aura patients, it was noticed that MEP threshold was significantly increased in the affected hemisphere compared with normal subjects and patients with unilateral migraine without aura. Subsquently, based on the theory that single-pulse TMS may disrupt cortical spreading depression, sTMS has been shown to be effective as an acute treatment for migraine with aura (Lipton & Pearlman 2010).
Modulating The Disease
A recent systematic review into the safety of TMS for migraine concluded that sTMS offers a safe, nonpharmacologic, nonbehavioral therapeutic approach to prescription drugs. Tens of thousands of subjects over two decades have undergone TMS for diagnostic, investigative, and therapeutic intervention trial purposes with minimal adverse events or side effects (Dodick et al 2010).
Novel approaches, such as theta burst stimulation, have suggested comparable effect-size but longer effect-durations. Further, it is hypothesised that the efficacy of TMS can be enhanced by repeating TMS-sessions or using EEG-gated TMS to tailor TMS to current neuronal state (Thut & Pasqual Leone 2010).
Links
References
- Dodick et al., Headache, 2010.
- Lipton & Pearlman, Neurotherapeutics, 2010.
- Thut & Pasqual Leone, Brain Topography, 2010.